travoprost Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 2716 157283-68-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • izba
  • travoprost
  • travaprost
  • travatan
  • travatanz
A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
  • Molecular weight: 500.56
  • Formula: C26H35F3O6
  • CLOGP: 3.92
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 3
  • TPSA: 96.22
  • ALOGS: -4.82
  • ROTB: 14

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 27, 2001 EMA
March 16, 2001 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 585.01 15.49 295 7748 92792 46585227
Intraocular pressure increased 391.95 15.49 107 7936 5850 46672169
Ocular hyperaemia 294.26 15.49 115 7928 19595 46658424
Eye irritation 291.30 15.49 109 7934 16505 46661514
Glaucoma 196.35 15.49 81 7962 15840 46662179
Eye pain 152.84 15.49 81 7962 27859 46650160
Product delivery mechanism issue 116.29 15.49 23 8020 291 46677728
Product packaging quantity issue 96.31 15.49 25 8018 1119 46676900
Eye pruritus 96.17 15.49 45 7998 11853 46666166
Visual acuity reduced 72.51 15.49 46 7997 22067 46655952
Foreign body sensation in eyes 62.85 15.49 20 8023 1856 46676163
Visual impairment 62.82 15.49 67 7976 66622 46611397
Eye allergy 51.54 15.49 13 8030 518 46677501
Dry eye 48.78 15.49 41 8002 30281 46647738
Vision blurred 48.40 15.49 64 7979 79644 46598375
Ocular discomfort 46.24 15.49 18 8025 3017 46675002
Intraocular pressure decreased 45.13 15.49 9 8034 119 46677900
Product quality issue 44.97 15.49 42 8001 35606 46642413
Product container issue 43.52 15.49 15 8028 1784 46676235
Product container seal issue 40.46 15.49 8 8035 101 46677918
Eye disorder 36.56 15.49 28 8015 18113 46659906
Liquid product physical issue 35.83 15.49 10 8033 590 46677429
Retinal disorder 34.63 15.49 12 8031 1449 46676570
Eye inflammation 32.61 15.49 15 8028 3794 46674225
Hypersensitivity 31.88 15.49 76 7967 150245 46527774
Normal tension glaucoma 31.02 15.49 6 8037 67 46677952
Growth of eyelashes 30.97 15.49 7 8036 173 46677846
Hypoacusis 30.96 15.49 27 8016 20942 46657077
Lacrimation increased 28.75 15.49 23 8020 15838 46662181
Subacute cutaneous lupus erythematosus 27.91 15.49 11 8032 1904 46676115
Conjunctival hyperaemia 27.51 15.49 11 8032 1978 46676041
Accidental exposure to product 26.89 15.49 25 8018 21056 46656963
Cataract 26.82 15.49 36 8007 45379 46632640
Eye swelling 25.95 15.49 24 8019 20079 46657940
Corneal disorder 25.59 15.49 10 8033 1693 46676326
Blepharal pigmentation 25.15 15.49 5 8038 65 46677954
Blindness 25.02 15.49 22 8021 17247 46660772
Hypertrophic cardiomyopathy 24.58 15.49 9 8034 1275 46676744
Photophobia 24.07 15.49 20 8023 14524 46663495
Optic nerve injury 24.04 15.49 7 8036 481 46677538
Open angle glaucoma 22.84 15.49 6 8037 281 46677738
Punctate keratitis 22.58 15.49 7 8036 596 46677423
Gastrointestinal bacterial infection 21.76 15.49 7 8036 672 46677347
Eye haemorrhage 21.45 15.49 14 8029 7038 46670981
Eyelid irritation 21.21 15.49 6 8037 372 46677647
Macular degeneration 21.17 15.49 14 8029 7191 46670828
Eyelid oedema 20.89 15.49 16 8027 10341 46667678
Intraocular pressure test abnormal 20.88 15.49 5 8038 160 46677859
Visual field defect 20.79 15.49 13 8030 6070 46671949
Rheumatoid arthritis 20.31 15.49 8 8035 240207 46437812
Gastroenteritis salmonella 20.23 15.49 6 8037 440 46677579
Myoglobin blood increased 20.06 15.49 8 8035 1428 46676591
Dark circles under eyes 19.95 15.49 6 8037 461 46677558
Expired product administered 19.18 15.49 12 8031 5610 46672409
Eye discharge 18.03 15.49 11 8032 4917 46673102
Corneal opacity 17.47 15.49 6 8037 706 46677313
Corneal epithelium defect 17.17 15.49 5 8038 344 46677675
Keratic precipitates 17.08 15.49 4 8039 116 46677903
Trabeculectomy 16.64 15.49 3 8040 22 46677997
Stag horn calculus 16.22 15.49 4 8039 145 46677874
Choroidal effusion 16.09 15.49 5 8038 429 46677590
Starvation 15.63 15.49 4 8039 169 46677850
Product packaging issue 15.50 15.49 6 8037 990 46677029

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 521.83 17.33 199 4619 34480 29913180
Intraocular pressure increased 229.00 17.33 67 4751 5053 29942607
Eye irritation 221.95 17.33 67 4751 5629 29942031
Ocular hyperaemia 176.26 17.33 63 4755 8980 29938680
Eye pain 93.29 17.33 43 4775 11746 29935914
Product delivery mechanism issue 83.34 17.33 15 4803 118 29947542
Glaucoma 71.16 17.33 29 4789 5879 29941781
Eye pruritus 67.65 17.33 25 4793 3902 29943758
Visual acuity reduced 61.99 17.33 36 4782 15810 29931850
Growth of eyelashes 58.20 17.33 10 4808 58 29947602
Blepharitis 48.59 17.33 14 4804 995 29946665
Cystoid macular oedema 44.41 17.33 12 4806 673 29946987
Expired product administered 37.70 17.33 15 4803 2854 29944806
Visual impairment 34.95 17.33 33 4785 30405 29917255
Foreign body sensation in eyes 32.71 17.33 9 4809 540 29947120
Erythema of eyelid 31.49 17.33 9 4809 621 29947039
Conjunctivitis 30.80 17.33 18 4800 7982 29939678
Eye inflammation 30.33 17.33 11 4807 1626 29946034
Vision blurred 29.54 17.33 35 4783 41781 29905879
Blindness 28.27 17.33 20 4798 12289 29935371
Lacrimation increased 27.58 17.33 16 4802 7000 29940660
Product packaging quantity issue 26.27 17.33 8 4810 688 29946972
Dry eye 26.09 17.33 15 4803 6453 29941207
Open angle glaucoma 24.37 17.33 6 4812 232 29947428
Ocular surface disease 24.24 17.33 5 4813 85 29947575
Conjunctivitis allergic 23.90 17.33 7 4811 527 29947133
Retinal detachment 23.85 17.33 13 4805 5047 29942613
Blindness unilateral 23.85 17.33 12 4806 3960 29943700
Eye discharge 22.66 17.33 9 4809 1704 29945956
Cataract 21.91 17.33 22 4796 21813 29925847
Product container issue 20.86 17.33 7 4811 823 29946837
Cerebellar stroke 20.14 17.33 5 4813 200 29947460
Vitreous floaters 20.06 17.33 10 4808 3234 29944426
Electrolyte depletion 19.84 17.33 5 4813 213 29947447
Product quality issue 18.99 17.33 19 4799 18755 29928905
Liquid product physical issue 18.51 17.33 5 4813 280 29947380
Hepatitis fulminant 18.23 17.33 10 4808 3931 29943729
Corneal oedema 17.73 17.33 7 4811 1305 29946355
Intraocular pressure decreased 17.42 17.33 4 4814 114 29947546

Pharmacologic Action:

SourceCodeDescription
ATC S01EE04 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Prostaglandin analogues
FDA CS M0017805 Prostaglandins
FDA EPC N0000175454 Prostaglandin Analog
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
CHEBI has role CHEBI:35674 antihypertensive
CHEBI has role CHEBI:39456 antiglaucoma agent
CHEBI has role CHEBI:50266 prodrugs
CHEBI has role CHEBI:66900 prostaglandin receptor agonists
CHEBI has role CHEBI:66981 ophthalmologicals

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Open-angle glaucoma indication 84494001 DOID:1067
Iritis contraindication 65074000 DOID:1406
Uveitis contraindication 128473001 DOID:13141
Cystoid macular edema contraindication 193387007 DOID:4447

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin F2-alpha receptor GPCR AGONIST Ki 7.28 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Prostaglandin E2 receptor EP3 subtype GPCR Ki 5.46 SCIENTIFIC LITERATURE

External reference:

IDSource
4021261 VUID
N0000148702 NUI
D01964 KEGG_DRUG
4021261 VANDF
C3832613 UMLSCUI
CHEBI:746859 CHEBI
CHEMBL1200799 ChEMBL_ID
D000069557 MESH_DESCRIPTOR_UI
7775 INN_ID
DB00287 DRUGBANK_ID
WJ68R08KX9 UNII
5282226 PUBCHEM_CID
7102 IUPHAR_LIGAND_ID
1539201 RXNORM
15936 MMSL
200905 MMSL
41255 MMSL
d04753 MMSL
009114 NDDF
129493000 SNOMEDCT_US
391664000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Travatan Z HUMAN PRESCRIPTION DRUG LABEL 1 0065-0260 SOLUTION/ DROPS 0.04 mg OPHTHALMIC NDA 22 sections
Travatan Z HUMAN PRESCRIPTION DRUG LABEL 1 0078-0946 SOLUTION/ DROPS 0.04 mg OPHTHALMIC NDA 25 sections
Travoprost Ophthalmic Solution, 0.004% HUMAN PRESCRIPTION DRUG LABEL 1 0378-9651 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost Ophthalmic Solution HUMAN PRESCRIPTION DRUG LABEL 1 0781-6185 SOLUTION/ DROPS 0.04 mg OPHTHALMIC NDA authorized generic 22 sections
Travoprost Ophthalmic HUMAN PRESCRIPTION DRUG LABEL 1 42571-130 SOLUTION 0.04 mg OPHTHALMIC ANDA 22 sections
Travatan Z HUMAN PRESCRIPTION DRUG LABEL 1 54868-5968 SOLUTION 0.04 mg OPHTHALMIC NDA 22 sections
Travoprost HUMAN PRESCRIPTION DRUG LABEL 1 60505-0593 SOLUTION 0.04 mg OPHTHALMIC ANDA 22 sections
Travoprost Ophthalmic Solution USP, 0.004%Travoprost Human Prescription Drug Label 1 62332-510 SOLUTION/ DROPS 0.04 mg OPHTHALMIC ANDA 22 sections